H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Summit Therapeutics stock is off to a slow start in 2025, but it still trades at a massive $13 billion valuation. The biotech ...

stocks here. Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.

Atossa Therapeutics (ATOS) announced its strategic decision to pursue a metastatic breast cancer indication for (Z)-endoxifen. Atossa believes ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, March 8, 2025 /PRNewswire/ -- As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights.

Pfizer (NYSE:PFE) and its partner Arvinas (NASDAQ:ARVN) for the experimental breast cancer drug vepdegestrant announced mixed initial results from a Phase 3 trial for the protein degrader on Tuesday.